Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Use of Nasal Phenylephrine in Infants With Bronchiolitis

This study has been completed.
Sponsor:
Information provided by:
Akron Children's Hospital
ClinicalTrials.gov Identifier:
NCT00373802
First received: September 7, 2006
Last updated: January 9, 2009
Last verified: January 2009

September 7, 2006
January 9, 2009
January 2005
June 2005   (final data collection date for primary outcome measure)
Respiratory Distress Assessment Index at 5 minutes, 60 minutes, and 180 minutes.
Same as current
Complete list of historical versions of study NCT00373802 on ClinicalTrials.gov Archive Site
Respiratory rate, oxygen saturation and use of supplemental oxygen at 5, 60, and 180 minutes.
Same as current
Not Provided
Not Provided
 
The Use of Nasal Phenylephrine in Infants With Bronchiolitis
A Randomized, Double-Blinded Placebo Control Trial of Nasal Phenylephrine in Infants With Bronchiolitis

Drops of either saline or phenylephrine are placed in the nose of infants less than 12 months of age to determine if it helps them to breathe easier.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Bronchiolitis
Drug: Phenylephrine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
June 2005
June 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age 4 weeks to 12 months; admitting diagnosis of bronchiolitis; admitted to hospital's bronchiolitis pathway, admitted during weekdays, need for nasal suctioning.

Exclusion Criteria:

  • Congenital heart disease, history of hypertension, previous wheezing, prior use of inhaled corticosteroids, gestational age at birth of <34 weeks.
Both
up to 12 Months
Not Provided
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00373802
NASAL #9579
Not Provided
Nathan Kraynack, M.D., Akron Children's Hospital
Akron Children's Hospital
Not Provided
Principal Investigator: Rachel Konda-Sundheim, MD, MD Children's Hospital Medical Center of Akron
Akron Children's Hospital
January 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP